Adeka (4401) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
18 Sep, 2026Executive summary
Net sales rose 15.2% year-over-year to ¥117.0 billion in Q1 FY2026, with operating profit up 42.7% to ¥15.6 billion and profit attributable to owners up 47.8% to ¥10.7 billion.
Growth was driven by strong demand in chemicals, semiconductor materials, and life science, while food products saw increased sales but decreased profit due to higher raw material costs.
Overseas sales ratio increased to 55.9%, with overseas sales up ¥9.9 billion year-over-year.
Full-year earnings and dividend forecasts were revised upward due to favorable business conditions and strong Q1 results.
Accelerated investments in growth domains and supply systems to meet future demand.
Financial highlights
Q1 net sales reached ¥117.0 billion, up ¥15.4 billion year-over-year.
Operating profit rose ¥4.6 billion to ¥15.6 billion; ordinary profit up 50.2% to ¥16.6 billion.
Quarterly profit increased ¥3.4 billion to ¥10.7 billion; EPS up ¥38.9 to ¥110.1.
Comprehensive income nearly doubled to ¥20,357 million from ¥10,227 million a year earlier.
Gross profit margin improved, with gross profit at ¥35,429 million versus ¥28,950 million last year.
Outlook and guidance
FY2026 forecast: ¥462.0 billion net sales, ¥50.0 billion operating and ordinary profit, ¥32.0 billion profit attributable to owners.
Forecasts revised upward from May: net sales +¥9.0 billion, operating profit +¥3.2 billion.
Annual dividend forecast raised to ¥132.00 per share, including a commemorative dividend; interim dividend at ¥66 per share.
Dividend payout ratio maintained at 40%+; 18 consecutive years without a dividend reduction.
Latest events from Adeka
- Record-high profits and sales, led by life science and semiconductor growth, with further gains forecast.4401
Q4 2026 - Strategic investments and innovation in semiconductor materials target rapid global growth.4401
Investor presentation - Profits and sales grew, led by Chemicals and Food Products, with raised outlook and Life Science loss.4401
Q1 2025 - Strong 1H FY2024 results and Chemicals growth led to higher guidance and dividend forecasts.4401
Q2 2025 - 3Q FY2024 saw higher sales and profits, driven by Chemicals and global expansion.4401
Q3 2025 - Record sales and profit growth driven by Chemicals, with continued expansion and higher dividends forecast.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026 - Life Science strength drove profit growth, offsetting Chemicals and Food Products weakness.4401
Q2 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 2026